Related Experiment Videos
Indomethacin for prevention of neonatal intraventricular hemorrhage
1University of Texas, Austin.
Insights
Intracerebral hemorrhage affects up to 50% of premature infants. Studies suggest indomethacin may help prevent or limit this condition, particularly low-grade cases, though more research is needed.
Area of Science:
- Neonatal Medicine
- Pediatric Neurology
- Pharmacology
Background:
- Intracerebral hemorrhage (ICH) affects up to 50% of premature infants, commonly in periventricular/intraventricular areas.
- ICH development is influenced by intravascular, vascular, and extravascular factors.
- Pharmacologic agents like indomethacin are explored for preventing intraventricular hemorrhage (IH).
Purpose of the Study:
- To evaluate the efficacy of indomethacin in preventing intraventricular hemorrhage (IH) in premature infants.
- To analyze the impact of indomethacin on cerebral blood flow and prostaglandin production.
Main Methods:
- Review of clinical studies assessing indomethacin for IH prevention in premature infants.
- Analysis of indomethacin's mechanism of action: inhibition of prostaglandin synthesis leading to cerebral vasoconstriction and reduced cerebral blood flow.
Main Results:
- Indomethacin inhibits prostaglandin production, causing cerebral vasoconstriction and reduced cerebral blood flow.
- Two large clinical studies indicate indomethacin is effective in preventing or limiting IH progression.
- Indomethacin appears most effective in reducing low-grade intraventricular hemorrhage.
Conclusions:
- No definitive recommendations for indomethacin use in IH prevention can be made currently.
- Further research is required to establish optimal dosage, duration, and serum concentrations for indomethacin therapy.
- Indomethacin shows promise in managing IH in premature infants, particularly for less severe cases.
Abstract:
Up to 50 percent of premature infants develop an intracerebral hemorrhage. Intracerebral hemorrhage in neonates occurs most frequently in the periventricular or intraventricular areas. Intravascular, vascular, and extravascular factors influence the development of hemorrhage. Pharmacologic therapies, such as phenobarbital, vitamin K, pancuronium bromide, vitamin E, and indomethacin, have been used in an attempt to prevent intraventricular hemorrhage (IH). Indomethacin inhibits prostaglandin production, which results in cerebral vasoconstriction and reduced cerebral blood flow. Several clinical studies have evaluated the role of indomethacin for the prevention of IH in premature infants. No definitive recommendations can be made regarding indomethacin use for this purpose. However, the two largest studies conducted to date have shown indomethacin to be effective in preventing or limiting the progression of IH. The drug appears to be most effective in reducing low-grade IH. More extensive research is needed to determine the most effective dose, duration, and serum concentration of indomethacin.